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in the ﬁrst 6 month period resulting in $6310 in lost wages. This
loss decreased in the 2nd 6 month period as 6.2% reported
increasing work status, 88% stayed the same, and 5.2% reported
additional decreases, which continued into the ﬁrst half of year 2.
Work loss then increased to 7% until 6 years post treatment
when it slowly decreased. Hours of work loss and gain over 10
years resulted in a weighted cumulative average wage loss of
$146,500. Those at moderate risk lost more wages than high or
low risk patients. Most wages were lost by those receiving andro-
gen deprivation therapy medications alone ($190,000), while
those receiving cryotherapy had the lowest wage loss ($99,500).
Radical prostatectomy treatment alone resulted in $142,100 lost
wages over 10 years. CONCLUSION: The wages lost after treat-
ment for prostate cancer are high. This is the ﬁrst long-term look
at prostate cancer workloss. Although most wage loss occurs in
the ﬁrst six months, substantial loss continues over the next ten
years.
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OBJECTIVE: Metastatic bone disease (MBD) and subsequent
skeletal-related events (SREs) are common complications second-
ary to solid tumors. We conducted a retrospective analysis of
US health insurance claims to examine the cost of SREs among
patients with MBD secondary to breast, lung, or prostate cancer.
METHODS: Data were obtained from i3’s Lab Rx Database
from May 1, 2000 to March 31, 2005. Patients were included if
they had at least two ICD-9 diagnoses of breast, lung, or prostate
cancer; at least two diagnoses of MBD; and at least one SRE on
or after the initial MBD diagnosis. SREs were deﬁned as a patho-
logical fracture, spinal cord compression, surgery to the bone, or
radiation to the bone and were identiﬁed using ICD-9 and CPT-4
codes. Patients had to be continuously insured for at least six
months prior to their ﬁrst SRE (index date) and one month after
their index date. Descriptive statistics were calculated and the
annual cost of SREs was estimated using Kaplan-Meier curves
to adjust for censoring. RESULTS: In the study period, 3584
patients were diagnosed with breast, lung, or prostate cancer and
MBD, and 1840 (51%) experienced at least one incident SRE.
Regardless of tumor type, patients were most frequently found to
have radiation therapy (86%–89%) followed by pathological
fracture (23%–29%), bone surgery (12%–16%), and spinal cord
compression (7%–9%). The adjusted mean costs associated with
SREs in the one year after the index SRE ranged from $12,469 to
$17,408, with the highest costs associated with radiation therapy
($5930 to $7152), pathological fracture ($3179 to $6624), and
bone surgery ($2218 to $2536). CONCLUSION: This analysis
of patients with cancer-related MBD revealed that the incidence
of SREs is high and their annual economic impact is substantial
regardless of tumor type.
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OBJECTIVE: Multiple myeloma (MM) is characterized by the
accumulation of monoclonal plasma cells and osteolytic bone
destruction and is complicated by skeletal-related events (SREs)
which are associated with signiﬁcant morbidity. We conducted a
retrospective analysis of US health insurance claims to examine
the cost of SREs among patients with MM and at least one SRE.
METHODS: Data were obtained from i3’s Lab Rx Database
from May 1, 2000 to May 31, 2005. Patients were included if
they had at least 2 ICD-9 diagnoses of MM (ICD-9 203.0x);
and at least 1 SRE on or after the initial MM diagnosis. SREs
were deﬁned as a pathological fracture, spinal cord compression,
surgery to the bone, or radiation to the bone and were identiﬁed
using ICD-9 and CPT-4 codes. Patients had be continuously
insured for at least six months prior to their ﬁrst SRE (index date)
and one month after their index date. Descriptive statistics were
calculated and annual cost of SREs was estimated using Kaplan-
Meier curves to adjust for censoring. RESULTS: In the study
period, 876 patients were diagnosed with MM, and 429 (49%)
experienced at least 1 incident SRE. The mean time from MM
diagnosis to index SRE was 259 days. Pathological fracture
(60%) and radiation therapy (59%) were the most frequently
experienced SREs followed by surgery to the bone (23%).
Among these patients, 61% had 1 type of SRE, 27% had 2 types
of SREs and 12% had 3 or more. The mean charges associated
with SREs in the 1 year post SRE was $20,285, with the highest
charges associated with pathological fracture ($11,370), fol-
lowed by bone surgery ($4,020), and radiation therapy ($2,966).
CONCLUSION: This analysis of patients with MM revealed
that the incidence of SREs is high and their annual economic
impact is substantial.
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OBJECTIVE: Document total medical resource utilization and
associated costs to the Medicare system for elderly patients with
high risk (stages IIB/C, IIIA/B, IIIC) or metastatic (stage IV)
malignant melanoma. METHODS: Data was taken from the
Surveillance, Epidemiology, and End Results (SEER)-Medicare
linked database combining clinical information on incident
cancer cases in the US between 1991 and 2002 with longitudinal
(1991–2005) Medicare claims. Subjects aged 65 years with 1
stage IIB or higher melanoma diagnosis were selected. Index
dates was deﬁned as the date of the ﬁrst observed stage IIB or
higher diagnosis. Utilization and costs were descriptively ana-
lyzed for each patient from their index date until death, inter-
ruption of beneﬁts coverage (6 months), or end of the database
(December 31, 2005). RESULTS: A total of 6470 subjects met all
inclusion criteria. Stage distribution was: IIB/C (38%); IIIA/B
(46%); IIIC (1%); IV (15%). Median follow-up was 56, 39, 16,
and 6 months for each stage, respectively. On average, patients
with stage IV disease incurred 3.1 hospital days per month,
compared to 0.5, 0.6, and 1.1 days per month for subjects
with stage IIB/C, IIIA/B, and IIIC melanoma, respectively (all
P < 0.001). Mean inpatient costs for stage IV disease were $3337
per patient per month, versus $589, $880, and $1465 for stages
IIB/C, IIIA/B, and IIIC, respectively (all P < 0.001). Total health
care costs, excluding prescription drugs, were $8190 per patient
per month for stage IV disease, compared to $1703, $2536,
$4880 for stages IIB/C, IIIA/B, and IIIC, respectively (all
P < 0.001). CONCLUSION: This study provides stage-speciﬁc
estimates of resource utilization and costs in high risk and meta-
static melanoma using real-world administrative data. Findings
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suggest that the cost burden of advanced melanoma to the Medi-
care system is high. Efforts to address the large unmet treatment
need in patients with advanced melanoma may result in cost
savings for Medicare.
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OBJECTIVE: To estimate direct medical costs of breast cancer
(BC) by stage of clinical disease in the Ginecology Hospital of
West Medical Center, Instituto Mexicano del Seguro Social
(IMSS), Guadalajara (GH). METHODS: Clinical data and
resource utilization were obtained individually from medical
records of patients who were breast cancer diagnosed and
received attention at GH between March 2005 and February
2007. This data was retrospectively collected with the following
inclusion criteria: 1) histopathologic-study conﬁrmed BC, 2)
recently diagnosed BC, and 3) absence of any other form of
cancer. Only direct medical costs were considered (from the
GH perspective) using a bottom up approach (medications,
chemotherapy, radiotherapy, hospitalization, laboratory tests
and surgery). Unitary costs were obtained from GH’s Manage-
ment. cost are expressed in USD and adjusted to December 2006.
A discount rate of 3% was used. Tests were applied in order to
deﬁne the censoring mechanism (according to Glick) to deﬁne the
adequate cost analysis method. To compare costs among stage
was use ANOVA. Mean Cost estimation (TMC) determinants
were obtained using a generalized linear Model (GLM).
RESULTS: A total of 160 patients were included, 40 in each stage
(I, II, III, IV), mean age 50 years (11), with a therapy duration
of 29 months (11). 82% of patients showed ductal-inﬁltranting
histologic type carcinoma. TMC per patient during the follow-up
period was ($20,612.00). Chemotherapy was the most costly
resource ($7526.10) followed by the visit to the specialist
and emergency room ($3581.88) and hospitalization costs
($3096.45). GLMxs statistically-signiﬁcant TMC determinants
were stage II, III and IV (p < 0.00), disease progression (p < 0.00)
death (p < 0.00) and age (p < 0.046). CONCLUSION: The direct
cost in medical attention increases with stage, progression of
disease or patient death, stage IV, less age, longer duration of
treatment and disease progression, effectively predicted major
costs.
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OBJECTIVE: To develop an economic analysis of the manage-
ment of pleural effusions in CML patients receiving dasatinib.
METHODS: A cost of treatment analysis was developed using
resource utilization data published for 48 patients with
dasatinib-related pleural effusions at a large cancer center. Costs
were derived from median reimbursements for relevant CPT
codes for outpatient services and medical literature for inpatient
services. The base case analysis assumed 100% incurred two
additional physician visits, two chest x-rays, and a course of
diuretics; 37.5% ECHO; 30% steroids; 24% recurrent effusions;
19% multiple thoracentesis procedures; 4% chest tube; 4%
Denver shunt; and 2% pericardial window. Sensitivity analyses
were conducted for types of procedures used. All costs were
adjusted to 2007 US dollars. RESULTS: Of pleural effusions
reported, 58% involved  25% of one lung volume and were
managed medically costing $750 per episode, including physician
visits, ECHO, chest X-rays and medications. The other 42% of
pleural effusions were more signiﬁcant, involving 26%–>75% of
one lung volume, with half of those patients requiring invasive
procedures. The cost of invasive procedures for inpatient man-
agement of pleural effusions was $10,616 for chest tube, $15,170
with pleural catheter, and $15,344 for pericardial window. The
cost of invasive outpatient management ranged from $713 for
ultrasound thoracentesis to $4598 for pleural catheter. The
average cost of treating a pleural effusion adverse event (includ-
ing all severity levels) ranged from $2062 to >$3000 depending
on whether thoracentesis or placement of pleural catheter was
utilized. Important drivers included recurrent effusions. CON-
CLUSION: This economic analysis based on actually observed
treatment patterns suggests that the management of pleural effu-
sions in CML patients receiving dasatinib is costly and requires
intensive resource utilization. Effective tyrosine kinase inhibitors
with lower rates of pleural effusions may represent clinically
and economically valuable alternatives for imatinib-resistant or
-intolerant CML patients.
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OBJECTIVE: The 2006 American Society of Clinical Oncology
guideline recommends primary prophylaxis (PP) with colony-
stimulating factor (CSF) for elderly patients with diffuse aggres-
sive lymphoma receiving chemotherapy, based on the assumption
of equal survival and studies showing that CSF saved costs by
reducing hospitalization from febrile neutropenia (FN). These
analyses examined only one cycle of chemotherapy, and did not
consider the costs of CSF in subsequent cycles, the strategy of
secondary prophylaxis (SP) or patients’ preferences. This study
examined the cost-effectiveness of PP with SP. METHODS: We
conducted a cost-utility analysis to compare PP with CSF to SP
with CSF for diffuse aggressive lymphoma. We used a Markov
cohort model with a time horizon of 8 cycles of chemotherapy
(i.e. 24 weeks), using a payer’s perspective (Ontario Ministry of
Health). Ontario’s 2006 health economic data was used. The
cost of hospitalization for FN was obtained from Ontario Case
Costing Initiative. Data for efﬁcacies of CSF, probabilities and
utilities were obtained from published literature. Monte Carlo
simulation was conducted. RESULTS: The ICER of PP to SP was
$739,999/QALY. One-way sensitivity analyses (willingness-to-
pay threshold =$100,000) showed that if PP were to be cost-
effective, the cost of hospitalization for FN had to be >$31,138
(2.5 times > base case), the cost of CSF per cycle <$96 (base case
= $1960), the risk of 1st cycle FN >48% (base case = 24%), or
the relative risk reduction of FN with CSF >97% (base case =
41%). Our result was robust to all variables. Second order
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